Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.

This article summarizes current health news, covering topics like potential bone loss from thyroid medication, dementia risks from wildfire smoke, and updates on pharmaceutical pricing policies. It ...

Live Updates Make sure to refresh this page periodically for updates. Notable Upgrades and Downgrades Today 12:10 pm Here are ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

In this edition of Law Talk, Attorney Megan Collins discusses the growing market for compounded weight-loss drugs and how you can stay safe when selecting certain medicines.

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

The Biden administration wants to expand access to popular weight loss drugs like Wegovy and Ozempic. The new proposal would ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

The Israeli military said it struck dozens of targets belonging to the Lebanese militant group Hezbollah before the start of a ceasefire on Wednesday.

Lebanon's prime minister on Wednesday said the army will reinforce its presence in the south, urging Israel to withdraw and respect the terms of the ceasefire reached with Hezbollah.

Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.Don't ...